Neuroone Medical Technologies Corporation · NASDAQ:NMTC
Neuroone Medical Technologies — Investor Presentation (April 2020)
23 slides from Neuroone Medical Technologies's investor presentation, Apr 6, 2020
Slide 1: NeuroOne Medical Technologies Corporation Company Overview
NeuroOne™ Medical Technologies Corporation Company Overview High - definition, minimally invasive platform electrode technology for recording & treatment of neurological disorders such as epilepsy, Parkinson’s Disease and Failed Back Surgery Syndrome
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENT S 2 NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION This presentation includes forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of h
Slide 3: Company Overview
COMPANY OVERVIEW Next generation electrode technology company specializing in development and commercialization of hi - definition thin film electrodes for the diagnosis and treatment of various neurological conditions such as epilepsy, Parkinson’s Disease and chronic pain due to failed back surgery
Slide 4: Product Summary
PRODUCT SUMMARY Evo™ Cortical Electrode Status A portfolio of hi - definition strip and grid thin film electrodes for recording brain activity - includes disposable cable assemb ly 510(k) received Evo™ sEEG Depth Electrode Status A portfolio of hi - definition depth thin film electrodes used for rec
Slide 5: Dire Need for Improved Electrode Technology
DIRE NEED FOR IMPROVED ELECTRODE TECHNOLOGY Despite large advances in therapeutics and surgical options over the last few decades, one area that has not seen significant improvement is electrode technology for neurological disorders . These disorders include epilepsy, Parkinson’s disease, essential
Slide 6: What physicians want in new electrode technology
What physicians want in new electrode technology 6 Less Invasive Surgeries • Reduced number of surgeries for diagnosis and treatment • Minimally invasive procedures • Reduced brain inflammation Improve surgical outcomes • Decreased procedure time • Ability to be more precise in targeting tissue for
Slide 7: Brain Electrode Market Overview
7 BRAIN ELECTRODE MARKET OVERVIEW Epilepsy Market Prevalence 1 Epilepsy Surgery Market Potential 1 Brain Tumor IOM Market Potential (cortical only) 1 700,000 Surgical Candidates 7 Million Electrodes a ~$5 Billion Revenue Potential b 240,000 Surgical Candidates 480,000 Electrodes c ~ $240 Million Rev
Slide 8: Evo Cortical Electrode
EVO™ CORTICAL ELECTRODE Thin Film Design Disposable Cables Clinical Evidence Greater Precision The thin film, flexible design provides new options for surgical placement. Single thin tail has less bulk while tunneling through the scalp and less incisions for possible infections. Eliminates the need
Slide 9: Thin-Film Depth Electrode
THIN - FILM DEPTH ELECTRODE 9 NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION Applications: Epilepsy surgery and awake brain mapping procedures Competitors: Ad - Tech, PMT, Integra, DIXI NeuroOne Advantages: Increase signal clarity / reduced noise Better tactile feedback during insertion into brain tissu
Slide 10: Combination Diagnostic + Ablation Depth Electrode for Epilepsy
COMBINATION DIAGNOSTIC + ABLATION DEPTH ELECTRODE FOR EPILEPSY NeuroOne Advantages vs Current Laser Technology : One procedure for diagnostic and therapeutic expected to save time, money and potentially improve d patient outcomes May provide bedside treatment capability saving significant time and c
Slide 11: Deep Brain Stimulation System
DEEP BRAIN STIMULATION SYSTEM NeuroOne Advantages: Utilizes sEEG depth electrode design Our high definition electrodes have been shown to detect micro seizures 1 which may improv e responsive stimulation a lgorithms Additional technology applications may be suitable for drug delivery 11 NEUROONE™ ME
Slide 12: Spinal Cord Stimulation Market Overview
SPINAL CORD STIMULATION MARKET OVERVIEW Market breakdown by diagnosis Global Market Growth Implant Procedure Locations NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION 12 Infinium Global Research. (2018). Spinal Cord Stimulation Market. Unpublished data on file. Failed Back Surgery Syndrome Complex Region
Slide 13: Spinal Cord Stimulation System
SPINAL CORD STIMULATION SYSTEM NeuroOne Advantages: Ability to place permanent electrodes percutaneously Expandable midsection allows electrode to extend without displacement “Scalability” of electrodes offer greater precision of targeted stimulation area Design allows for use for trial period and p
Slide 14: Bridging the Gap – Artificial Intelligence (A.I.)
BRIDGING THE GAP – ARTIFICIAL INTELLIGENCE (A.I.) Damaged neurons can cause a break in neuron to neuron connectivity: etiology for many neurological disorders Successful treatments achieved by implanting small wires to record and reintroduce the natural signal back Elon Musk and others have started
Slide 15: Target Product Development Timeline
NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION 15 TARGET PRODUCT DEVELOPMENT TIMELINE¹ Cortical Electrode Product Testing 510k Launch Diagnostic Depth Electrode Product Development Product Testing 510k Launch Dx + Ablation Depth Electrode Product Development Product Testing 510k + data Launch MI Cortica
Slide 16: Intellectual Property to Date
INTELLECTUAL PROPERTY TO DATE 16 NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION In - Licensed Patents From WARF At UW - Madison Patent No. Issue Date Title Abstract Summary Other Information to discuss US 8,483,794 July 2013 Method for implanting an electrode that unfurls in response to a predetermined
Slide 17: Scientific Advisory Board
SCIENTIFIC ADVISORY BOARD Greg Worrell MD, PhD, Chairman of the Scientific Advisory Board World renowned neurologist at Mayo Clinic. Recognized by the American Epilepsy Society (AES), the American Academy of Neurology (AAN), the American Neurological Association (ANA), and the Citizens United in Res
Slide 18: Company Management
COMPANY MANAGE MENT Dave Rosa, President and Chief Executive Officer An entrepreneur with three decades of experience in the medical device industry spanning a variety of technologies and products. In addition to CEO roles with early stage medical device companies, Mr. Rosa’s background also include
Slide 19: Board of Directors
BOARD OF DIRECTORS Paul Buckman, Chairman of the Board Mr. Buckman is currently the President of North America of LivaNova PLC, a London - based medical device manufacturer, publicly trading on the N asdaq . The Company develops devices used for cardiac surgery, neuromodulation, and cardiac rhythm m
Slide 20: Select Financial Information
SELECT FINANCIAL INFORMATION Listed on OTCQB: NMTC Financial Data 1 Price: $ 2.33 90 - Day Price Range: $ 1.83 - $ 3.73 Daily Volume – Last 30 Day Average: 9,737 Market Capitalization: $ 32.3 M illion Shares Outstanding: 13.9 Million Shares in Float ~ 6.3 Million Convertible Notes – Due May 1, 2020
Slide 21: 2020 Corporate Goals
2020 CORPORATE GOALS Expected FDA 510(k) submission for 2 nd product First commercial sale for human use Uplist to exchange Conclusion of PMT litigation Secure at least one DARPA or NIH grant for new technologies 21 NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION
Slide 22: Investment Highlights
INVESTMENT HIGHLIGHTS Substantial m arket opportunity Disruptive, patented technologies • Address a significant and unmet need • E xpectation – substantially improved outcomes • Meet the need to lower costs • Established reimbursement Majority of NeuroOne’s products expect U.S. FDA 510(k) process Pl
Slide 23: Contact
C ON T A C T Dave Rosa President and Chief Executive Officer Email: daver@n1mtc.com 23 NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION
NeuroOne Medical Technologies — Investor Presentation (April 2020) on 6ix